TrumpRx Analysis: One-Third of Listed Drugs Still Cost More Than in the UK
By FieldPulse Staff · March 18, 2026
Tags: strategy, leadership
Reuters analysis finds ~1 in 3 TrumpRx drugs still cost more than in the UK. Program is voluntary with no enforcement, and political opposition to MFN legislation is growing.
A Reuters analysis published March 18, 2026 found that approximately one-third of the 54 drugs listed on TrumpRx.gov — the White House drug pricing platform launched earlier this year — remain more expensive than what patients pay in the United Kingdom, even after voluntary discounts offered by participating manufacturers.
Among the drugs still priced higher than UK equivalents: Pfizer's Xeljanz (JAK inhibitor), AstraZeneca's Farxiga (SGLT2 inhibitor), and several GSK inhalers, which are 67–82% cheaper in Britain.
Critics including Harvard's Aaron Kesselheim noted the program is entirely voluntary with no enforcement mechanism, and does not address the underlying pricing structures that keep U.S.
list prices elevated.
Novo Nordisk and Johnson & Johnson both flagged financial exposure from most-favored-nation (MFN) pricing deals in recent earnings guidance.
The analysis comes amid a broader political fight: a coalition of more than 50 conservative and free-market groups signed a letter this week calling MFN pricing "imported socialist price controls," complicating the White House's push to codify the program through legislation.